Published in Cell Cycle on July 01, 2011
Akt-mediated phosphorylation of Bmi1 modulates its oncogenic potential, E3 ligase activity, and DNA damage repair activity in mouse prostate cancer. J Clin Invest (2012) 2.03
The ATM protein kinase and cellular redox signaling: beyond the DNA damage response. Trends Biochem Sci (2011) 1.91
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget (2012) 1.85
PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy. Clin Cancer Res (2011) 1.46
PI3K-independent AKT activation in cancers: a treasure trove for novel therapeutics. J Cell Physiol (2012) 1.35
DNA damage and the balance between survival and death in cancer biology. Nat Rev Cancer (2015) 1.25
Beyond DNA repair: DNA-PK function in cancer. Cancer Discov (2014) 1.16
The role of AKT/mTOR pathway in stress response to UV-irradiation: implication in skin carcinogenesis by regulation of apoptosis, autophagy and senescence. Int J Mol Sci (2013) 1.04
Dynamic inhibition of ATM kinase provides a strategy for glioblastoma multiforme radiosensitization and growth control. Cell Cycle (2012) 1.04
Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells. Cancer Biol Ther (2013) 0.96
Role of AKT signaling in DNA repair and clinical response to cancer therapy. Neuro Oncol (2014) 0.94
Tug of war between survival and death: exploring ATM function in cancer. Int J Mol Sci (2014) 0.92
BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts. Br J Cancer (2015) 0.92
ATM regulates Cdt1 stability during the unperturbed S phase to prevent re-replication. Cell Cycle (2013) 0.91
DNA-damage-induced nuclear export of precursor microRNAs is regulated by the ATM-AKT pathway. Cell Rep (2013) 0.90
The influence of AKT isoforms on radiation sensitivity and DNA repair in colon cancer cell lines. Tumour Biol (2013) 0.89
Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer. Int J Mol Sci (2013) 0.89
Therapeutic Implications for Overcoming Radiation Resistance in Cancer Therapy. Int J Mol Sci (2015) 0.86
Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells. Mol Carcinog (2012) 0.85
Modification of Akt by SUMO conjugation regulates alternative splicing and cell cycle. Cell Cycle (2013) 0.82
Recent progress in genetics of aging, senescence and longevity: focusing on cancer-related genes. Oncotarget (2012) 0.82
Akt promotes tumorigenesis in part through modulating genomic instability via phosphorylating XLF. Nucleus (2015) 0.81
Translational initiation regulated by ATM in dendritic cells development. Cell Death Dis (2014) 0.81
MutS homologue hMSH4: interaction with eIF3f and a role in NHEJ-mediated DSB repair. Mol Cancer (2013) 0.80
MRE11 and ATM AKTivate pro-survival signaling. Cell Cycle (2011) 0.80
The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells. Cancers (Basel) (2015) 0.79
Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations. Clin Cancer Res (2015) 0.77
Dual targeting of PI3K and MEK enhances the radiation response of K-RAS mutated non-small cell lung cancer. Oncotarget (2016) 0.77
Differential expression of thymic DNA repair genes in low-dose-rate irradiated AKR/J mice. J Vet Sci (2013) 0.77
Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment. Mol Cell Oncol (2014) 0.76
Nuclear Acetyl-CoA Production by ACLY Promotes Homologous Recombination. Mol Cell (2017) 0.75
Dual Targeting of Akt and mTORC1 Impairs Repair of DNA Double-Strand Breaks and Increases Radiation Sensitivity of Human Tumor Cells. PLoS One (2016) 0.75
Targeting the AKT pathway: Repositioning HIV protease inhibitors as radiosensitizers. Indian J Med Res (2016) 0.75
DNA double-strand breaks make bedfellows of ATM and AKT. Cell Cycle (2011) 0.75
Activating Akt1 mutations alter DNA double strand break repair and radiosensitivity. Sci Rep (2017) 0.75
The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures. BMC Cancer (2017) 0.75
Enhanced dependency of KRAS-mutant colorectal cancer cells on RAD51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae. Mol Oncol (2017) 0.75
Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry. Nature (2002) 37.66
Orchestration of the DNA-damage response by the RNF8 ubiquitin ligase. Science (2007) 7.61
RNF168 binds and amplifies ubiquitin conjugates on damaged chromosomes to allow accumulation of repair proteins. Cell (2009) 6.89
The RIDDLE syndrome protein mediates a ubiquitin-dependent signaling cascade at sites of DNA damage. Cell (2009) 5.96
The CRAPome: a contaminant repository for affinity purification-mass spectrometry data. Nat Methods (2013) 4.34
A phosphatase complex that dephosphorylates gammaH2AX regulates DNA damage checkpoint recovery. Nature (2005) 4.33
Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol (2013) 3.76
Human tissues contain CD141hi cross-presenting dendritic cells with functional homology to mouse CD103+ nonlymphoid dendritic cells. Immunity (2012) 3.58
A cell cycle-dependent regulatory circuit composed of 53BP1-RIF1 and BRCA1-CtIP controls DNA repair pathway choice. Mol Cell (2013) 3.55
Regulation of DNA damage responses by ubiquitin and SUMO. Mol Cell (2013) 3.43
Mitosis inhibits DNA double-strand break repair to guard against telomere fusions. Science (2014) 3.31
Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol Cell Biol (2002) 3.08
A genome-wide screen identifies the evolutionarily conserved KEOPS complex as a telomere regulator. Cell (2006) 2.71
Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Cancer Res (2010) 2.68
53BP1 is a reader of the DNA-damage-induced H2A Lys 15 ubiquitin mark. Nature (2013) 2.64
Non-canonical inhibition of DNA damage-dependent ubiquitination by OTUB1. Nature (2010) 2.47
An allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzyme. Cell (2011) 2.35
Xrcc4 physically links DNA end processing by polynucleotide kinase to DNA ligation by DNA ligase IV. EMBO J (2004) 2.24
Saccharomyces cerevisiae Rad9 acts as a Mec1 adaptor to allow Rad53 activation. Curr Biol (2005) 2.20
Regulatory ubiquitylation in response to DNA double-strand breaks. DNA Repair (Amst) (2009) 2.17
PP4 is a gamma H2AX phosphatase required for recovery from the DNA damage checkpoint. EMBO Rep (2008) 2.09
Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol Cell Biol (2004) 2.09
The molecular architecture of the mammalian DNA repair enzyme, polynucleotide kinase. Mol Cell (2005) 2.09
Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. Cancer Res (2005) 2.02
Significant conservation of synthetic lethal genetic interaction networks between distantly related eukaryotes. Proc Natl Acad Sci U S A (2008) 2.01
Inverse relationship between biochemical outcome and acute toxicity after image-guided radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2011) 2.00
Structural and functional versatility of the FHA domain in DNA-damage signaling by the tumor suppressor kinase Chk2. Mol Cell (2002) 1.99
Gold nanoparticles as radiation sensitizers in cancer therapy. Radiat Res (2010) 1.97
The ubiquitous role of ubiquitin in the DNA damage response. DNA Repair (Amst) (2010) 1.94
Ionizing radiation activates AMP-activated kinase (AMPK): a target for radiosensitization of human cancer cells. Int J Radiat Oncol Biol Phys (2010) 1.89
Elg1 forms an alternative PCNA-interacting RFC complex required to maintain genome stability. Curr Biol (2003) 1.88
Systematic identification of fragile sites via genome-wide location analysis of gamma-H2AX. Nat Struct Mol Biol (2010) 1.87
A viral E3 ligase targets RNF8 and RNF168 to control histone ubiquitination and DNA damage responses. EMBO J (2010) 1.75
Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res (2008) 1.70
Tandem protein interaction modules organize the ubiquitin-dependent response to DNA double-strand breaks. Mol Cell (2012) 1.62
OTUB1 co-opts Lys48-linked ubiquitin recognition to suppress E2 enzyme function. Mol Cell (2012) 1.58
Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma. J Clin Invest (2012) 1.57
Atomic structure of the KEOPS complex: an ancient protein kinase-containing molecular machine. Mol Cell (2008) 1.51
Problems with co-funding in Canada. Science (2005) 1.48
PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy. Clin Cancer Res (2011) 1.46
TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair. Clin Cancer Res (2013) 1.45
APLF (C2orf13) facilitates nonhomologous end-joining and undergoes ATM-dependent hyperphosphorylation following ionizing radiation. DNA Repair (Amst) (2008) 1.44
MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer. Cancer Res (2010) 1.44
A strategy for modulation of enzymes in the ubiquitin system. Science (2013) 1.43
Promyelocytic leukemia nuclear bodies behave as DNA damage sensors whose response to DNA double-strand breaks is regulated by NBS1 and the kinases ATM, Chk2, and ATR. J Cell Biol (2006) 1.43
From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol (2012) 1.42
Rnf8 deficiency impairs class switch recombination, spermatogenesis, and genomic integrity and predisposes for cancer. J Exp Med (2010) 1.40
A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia. Radiother Oncol (2008) 1.39
The insulator binding protein CTCF associates with the nuclear matrix. Exp Cell Res (2003) 1.35
The F-box protein Dia2 overcomes replication impedance to promote genome stability in Saccharomyces cerevisiae. Genetics (2006) 1.33
The MMS22L-TONSL complex mediates recovery from replication stress and homologous recombination. Mol Cell (2010) 1.32
Novel chemical enhancers of heat shock increase thermal radiosensitization through a mitotic catastrophe pathway. Cancer Res (2007) 1.32
Push back to respond better: regulatory inhibition of the DNA double-strand break response. Nat Rev Mol Cell Biol (2013) 1.29
The p53 protein family and radiation sensitivity: Yes or no? Cancer Metastasis Rev (2004) 1.24
The RNF8/RNF168 ubiquitin ligase cascade facilitates class switch recombination. Proc Natl Acad Sci U S A (2009) 1.24
Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response. Clin Cancer Res (2013) 1.24
Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy. Cancer (2012) 1.23
Genomic instability, defective spermatogenesis, immunodeficiency, and cancer in a mouse model of the RIDDLE syndrome. PLoS Genet (2011) 1.23
De novo telomere formation is suppressed by the Mec1-dependent inhibition of Cdc13 accumulation at DNA breaks. Genes Dev (2010) 1.22
Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells. Radiother Oncol (2005) 1.22
Treatment of radiation proctitis with hyperbaric oxygen. Radiother Oncol (2005) 1.18
Late residual gamma-H2AX foci in murine skin are dose responsive and predict radiosensitivity in vivo. Radiat Res (2010) 1.17
Evidence for the direct binding of phosphorylated p53 to sites of DNA breaks in vivo. Cancer Res (2005) 1.16
Tumor hypoxia, DNA repair and prostate cancer progression: new targets and new therapies. Future Oncol (2007) 1.15
Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets. Semin Radiat Oncol (2010) 1.14
Defective DNA strand break repair after DNA damage in prostate cancer cells: implications for genetic instability and prostate cancer progression. Cancer Res (2004) 1.13
Comparing oxygen-sensitive MRI (BOLD R2*) with oxygen electrode measurements: a pilot study in men with prostate cancer. Int J Radiat Biol (2009) 1.13
Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation. Radiother Oncol (2012) 1.12
Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents. J Clin Oncol (2003) 1.11
Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity. Mol Cancer Ther (2009) 1.11
Ccr4 contributes to tolerance of replication stress through control of CRT1 mRNA poly(A) tail length. J Cell Sci (2006) 1.11
"Contextual" synthetic lethality and/or loss of heterozygosity: tumor hypoxia and modification of DNA repair. Clin Cancer Res (2010) 1.11
Rad6-Rad18 mediates a eukaryotic SOS response by ubiquitinating the 9-1-1 checkpoint clamp. Cell (2008) 1.10
Radiation and new molecular agents part I: targeting ATM-ATR checkpoints, DNA repair, and the proteasome. Semin Radiat Oncol (2006) 1.08
High-resolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer. Prostate (2009) 1.08
Microscopic imaging of DNA repair foci in irradiated normal tissues. Int J Radiat Biol (2009) 1.08
Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer. J Pathol (2012) 1.07
A screen for suppressors of gross chromosomal rearrangements identifies a conserved role for PLP in preventing DNA lesions. PLoS Genet (2007) 1.06
CDC5 inhibits the hyperphosphorylation of the checkpoint kinase Rad53, leading to checkpoint adaptation. PLoS Biol (2010) 1.05
Proliferating cell nuclear antigen (PCNA) may function as a double homotrimer complex in the mammalian cell. J Biol Chem (2005) 1.03
Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53. Mol Cancer Ther (2008) 1.03
Tumor cell kill by c-MYC depletion: role of MYC-regulated genes that control DNA double-strand break repair. Cancer Res (2010) 1.02
miRNA-95 mediates radioresistance in tumors by targeting the sphingolipid phosphatase SGPP1. Cancer Res (2013) 1.02
Uroporphyrinogen decarboxylase is a radiosensitizing target for head and neck cancer. Sci Transl Med (2011) 1.00
Interaction proteomics identify NEURL4 and the HECT E3 ligase HERC2 as novel modulators of centrosome architecture. Mol Cell Proteomics (2012) 1.00
Reconstitution and characterization of eukaryotic N6-threonylcarbamoylation of tRNA using a minimal enzyme system. Nucleic Acids Res (2013) 1.00
Analysis of variants in DNA damage signalling genes in bladder cancer. BMC Med Genet (2008) 0.99
Inhibition of breast cancer local relapse by targeting p70S6 kinase activity. J Mol Cell Biol (2013) 0.99
Discordance between phosphorylation and recruitment of 53BP1 in response to DNA double-strand breaks. Cell Cycle (2012) 0.98
NKX3.1 haploinsufficiency is prognostic for prostate cancer relapse following surgery or image-guided radiotherapy. Clin Cancer Res (2011) 0.96